BD Reports the Acquisition of Edwards Lifesciences' Critical Care Product Group, Enhancing its Smart Connected Care Solutions
Shots:
- BD has agreed to acquire Edwards Lifesciences’ Critical Care product group, strengthening its portfolio of smart connected care solutions for $4.2B in cash
- As per the agreement, BD will fund $1B in cash and $3.2B in new debt with a net leverage of about 3x at closing, with plans to reduce it to 2.5x within 12-18mos. using free cash flow. Transaction is contingent upon customary regulatory reviews and closing conditions and will conclude at YE’24
- The acquisition will further add Critical Care's AI & ML-based gold-standard Swan Ganz pulmonary artery catheter, minimally invasive sensors, noninvasive cuffs, tissue oximetry sensors & monitors to BD’s portfolio, enabling improved decision-making capabilities
Ref: BD | Image: BD
Related News:- BD Receives the US FDA’s Clearance for Infectious Vaginitis Test for Use in High Throughput Platform
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
